Abstract
Due to the radiosensitivity of the lung, toxic endpoints, in the form of radiation pneumonitis and pulmonary fibrosis, are relatively frequent outcomes following radiation treatment of thoracic neoplasms. Because of the potential lethal nature of these normal tissue reactions, they not only lead to quality-of-life issues in survivors, but also are deemed dose-limiting and thereby compromise treatment. The mitigation and treatment of lung normal tissue late effects has therefore been the goal of many investigations; however, the complexity of both the organ itself and its response to injury has resulted in little success. Nonetheless, current technology allows us to propose likely targets that are either currently being researched or should be considered in future studies.
Keywords: Radiation, lung, pneumonitis, pulmonary fibrosis, pulmonary, neoplasms, bronchiole, endothelium, fibroblasts, FDA, (ROS), (SOD), Mn-SOD, (L-NAME), (iNOS), DNA damage, (SP-A), (COX-2), HMG-CoA, (MCP-1), Cytokine, (TNF), IL-1, TGF-ß, RAS, ACE
Current Drug Targets
Title: Treatment for Radiation-Induced Pulmonary Late Effects: Spoiled for Choice or Looking in the Wrong Direction?
Volume: 11 Issue: 11
Author(s): Jacqueline P. Williams, Carl J. Johnston and Jacob N. Finkelstein
Affiliation:
Keywords: Radiation, lung, pneumonitis, pulmonary fibrosis, pulmonary, neoplasms, bronchiole, endothelium, fibroblasts, FDA, (ROS), (SOD), Mn-SOD, (L-NAME), (iNOS), DNA damage, (SP-A), (COX-2), HMG-CoA, (MCP-1), Cytokine, (TNF), IL-1, TGF-ß, RAS, ACE
Abstract: Due to the radiosensitivity of the lung, toxic endpoints, in the form of radiation pneumonitis and pulmonary fibrosis, are relatively frequent outcomes following radiation treatment of thoracic neoplasms. Because of the potential lethal nature of these normal tissue reactions, they not only lead to quality-of-life issues in survivors, but also are deemed dose-limiting and thereby compromise treatment. The mitigation and treatment of lung normal tissue late effects has therefore been the goal of many investigations; however, the complexity of both the organ itself and its response to injury has resulted in little success. Nonetheless, current technology allows us to propose likely targets that are either currently being researched or should be considered in future studies.
Export Options
About this article
Cite this article as:
P. Williams Jacqueline, J. Johnston Carl and N. Finkelstein Jacob, Treatment for Radiation-Induced Pulmonary Late Effects: Spoiled for Choice or Looking in the Wrong Direction?, Current Drug Targets 2010; 11 (11) . https://dx.doi.org/10.2174/1389450111009011386
DOI https://dx.doi.org/10.2174/1389450111009011386 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Electrical Impedance Scanning - A New Diagnostic Tool in Cancer Detection: Current Status and Recent Developments
Current Medical Imaging Src Kinase Inhibitors: An Update on Patented Compounds
Current Medicinal Chemistry Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry Oncogenomic Approaches in Exploring Gain of Function of Mutant p53
Current Genomics The Role of XRCC4 in Carcinogenesis and Anticancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery Imaging Virus-Associated Cancer
Current Pharmaceutical Design Hardware and Software Approaches to Multi-Modality Imaging
Current Medical Imaging Perspectives On Membrane-associated Progesterone Receptors As Prospective Therapeutic Targets
Current Drug Targets The Prodrugs of 5-Fluorouracil
Current Medicinal Chemistry - Anti-Cancer Agents Identification of a RhoA- and SRF-Dependent Mechanism of Androgen Action that is Associated with Prostate Cancer Progression
Current Drug Targets PPARγ and Its Ligands: Potential Antitumor Agents in the Digestive System
Current Stem Cell Research & Therapy Epigenetic Targets and their Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Adipose Stem Cells and Skin Repair
Current Stem Cell Research & Therapy Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies
Clinical Cancer Drugs Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets Elucidating Molecular Interactions of Ten Natural Compounds Targeting E6 HPV High Risk Oncoproteins Using Microsecond Molecular Dynamics Simulations
Medicinal Chemistry Glucans as Biological Response Modifiers
Endocrine, Metabolic & Immune Disorders - Drug Targets EBV-Related Malignancies, Outcomes and Novel Prevention Strategies
Infectious Disorders - Drug Targets Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Current Cancer Drug Targets Possible Involvement of TRP Channels in Cardiac Hypertrophy and Arrhythmia
Current Topics in Medicinal Chemistry